Literature DB >> 31129195

Management of the Clinically Negative (cN0) Groin Penile Cancer Patient: A Review.

Mohamed H Kamel1, Mahmoud I Khalil1, Rodney Davis1, Philippe E Spiess2.   

Abstract

To determine the role of noninvasive, minimally invasive diagnostic modalities and current management recommendations for cN0 PNC, a literature review using PubMed and Web of Science search engines were conducted. We found that for predicting ILN+: physical exam has limitations, nomograms are not validated, conventional computerized tomography/magnetic resonance imaging/positron imaging tomography scans have minimal role, and dynamic sentinel lymph node biopsy is the most reliable minimally invasive modality. Adverse pathological features: G3, stage ≥ T2, presence of LVI, and rare histopathological variants are important predictors of ILN+ and their presence warrants prophylactic ILND or dynamic sentinel lymph node biopsy. In the absence of these adverse pathological features conservative management is justified.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31129195     DOI: 10.1016/j.urology.2019.05.005

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  3 in total

1.  Potential Receptors for Targeted Imaging of Lymph Node Metastases in Penile Cancer.

Authors:  Christa A M van der Fels; Selma Palthe; Henk Buikema; Marius C van den Heuvel; Annemarie Leliveld; Igle Jan de Jong
Journal:  Diagnostics (Basel)       Date:  2020-09-15

Review 2.  Robot-assisted endoscopic inguinal lymphadenectomy: A review of current outcomes.

Authors:  Gilberto José Rodrigues; Giuliano Betoni Guglielmetti; Marcelo Orvieto; Kulthe Ramesh Seetharam Bhat; Vipul R Patel; Rafael Ferreira Coelho
Journal:  Asian J Urol       Date:  2020-08-26

3.  Nomogram prediction of overall survival based on log odds of positive lymph nodes for patients with penile squamous cell carcinoma.

Authors:  Wenwen Zheng; Kangqi Li; Weiwei Zhu; Yuexia Ding; Qingna Wu; Qiling Tang; Congxiao Lu; Quan Zhao; Shengqiang Yu; Chenyu Guo
Journal:  Cancer Med       Date:  2020-06-10       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.